¹Ù·Î°¡±â ¸Þ´º

¹Ù·Î°¡±â ¸Þ´º º»¹®³»¿ë ¹Ù·Î°¡±â ¸ÞÀθ޴º ¹Ù·Î°¡±â

ÁÖ¿ä¾È³»

HOME »çÀÌÆ®¸Ê

FONT SIZE

ÆùƮũ±â Å°¿ò 100% 110% 120% 130% 140% ÆùƮũ±â ÁÙÀÓ
¸Þ´ºº¸±â
 
Á¦¸ñ
7/16 ¹ßÇ¥³í¹®ÀÔ´Ï´Ù.
ÀÛ¼ºÀÏ
2022-07-15
Á¶È¸¼ö
206


¾È³çÇϼ¼¿ä ö±Õ ÀÔ´Ï´Ù.

À̹ø¿¡ ¹ßÇ¥µå¸± ³í¹®ÀÇ Á¦¸ñÀº 

"IFN-γ–dependent tumor-antigen cross-presentation by lymphatic endothelial cells promotes their killing by T cells and inhibits metastasis" À̸ç, 

Áö³­´Þ 8ÀÏ (2022.06.08), SCIENCE ADVACNES¿¡ ÃâÆÇµÈ ³í¹®ÀÔ´Ï´Ù. 

¾ÏÀÇ ÀüÀÌ °úÁ¤¿¡´Â Lymphatic vesselÀÌ ÁÖ¿äÇÑ ¿µÇâÀ» ³¢Ä¡´Â ¹Ý¸é Lymphatic vessel (LV) °ú ±×¸¦ ±¸¼ºÇÏ´Â lymphatic endothelial cells (LECs)ÀÌ 

Ç׿øÁ¦½Ã¿Í, CTLÀÇ ÀÛ¿ëÀÇ °üÁ¡¿¡¼­ ¾î¶² »óÈ£°ü°è¸¦ °®´ÂÁö´Â À߾˷ÁÁ® ÀÖÁö ¾Ê¾Ò´Âµ¥, 

º» ³í¹®Àº lymphatic vesselÀ» Àß Çü¼ºÇϵµ·Ï modified µÈ tumor model (B16F10-OVA+VC+)¸¦ ÀÌ¿ëÇÏ¿© À̸¦ Ž±¸ÇÏ¿´½À´Ï´Ù. 

CTLÀÇ ±â´É¿¡ ÇʼöÀûÀΠIFN-γÀÇ ¹ßÇöÀº ¿ÀÈ÷·Á LECsÀÇ immuno suppressive markerÀÇ ¹ßÇöÀ» ³ôÀÌ´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ¾ú´Âµ¥, 

ÀÌ ³í¹®¿¡¼­´Â tumor ³»¿¡ ³ôÀº ¹Ðµµ·Î effector T cell ÀÌ Á¸ÀçÇÏ´Â °æ¿ì LECÀÇ apoptosis¿Í LVÀÇ Çü¼ºÀÌ ¾ïÁ¦µÇ¸ç, ÀÌ °úÁ¤Áß¿¡ tumor antigenÀÌ release µÇ¾î 

Ç׿ø ƯÀÌÀûÀÎ T cellÀÇ ¹ÝÀÀÀ» Áõ´ë ½ÃÅ°¸ç ÀÌ °úÁ¤ÀÌ IFN-γ ¿¡ ÀÇÁ¸ÀûÀÓÀ» ¹àÇû½À´Ï´Ù. 

Åä¿äÀÏ¿¡ ºË°Ú½À´Ï´Ù. 

ö±Õ ¿Ã¸².

³í¹® ¸µÅ© : https://www.science.org/doi/abs/10.1126/sciadv.abl5162
÷ºÎÆÄÀÏ:
÷ºÎÆÄÀÏÀÌ ¾ø½À´Ï´Ù.
´ÙÀ½±Û
7/23 ¹ßÇ¥³í¹® ÀÔ´Ï´Ù
/ °ü¸®ÀÚ
¾È³çÇϼ¼¿ä. À̹øÁÖ ¹ßÇ¥ÀÚ ¿µÁø ÀÔ´Ï´Ù. Á¦°¡ À̹øÁÖ Åä¿äÀÏ¿¡ ¹ßÇ¥ ÇÒ ³í¹®Àº ¿ÃÇØ JEM¿¡ ÃâÆÇµÈ "Angiotensin II enhances group 2 innate lymphoid cellresponses via AT1a during airway inflammation" ÀÔ´Ï´Ù. ILC2´Âairway inflammationÀ» À¯¹ßÇÏ´Â Áß¿äÇÑ ¸é¿ª¼¼Æ÷ Áß Çϳª·Î ÃÖ±Ù¿¡ ÁÖ¸ñ¹Þ°í..
ÀÌÀü±Û
7/16 ¹ßÇ¥³í¹®ÀÔ´Ï´Ù.
/ °ü¸®ÀÚ
¾È³çÇϼ¼¿ä, À̹øÁÖ ¹ßÇ¥ÀÚ ´ÙÁ¤ÀÔ´Ï´Ù. Á¦°¡ À̹ø¿¡ ¼±Á¤ÇÑ ³í¹®Àº2020³â Nature immunology¿¡ ÃâÆÇµÈ 'BATF3 programs CD8+ T cell memory'ÀÔ´Ï´Ù. ¿ì¼±BATF3´Â ÀÌÀü±îÁöconventional DCÀÇdevelopment¿¡ Áß¿äÇÑ Àü»çÀÎÀڷνá Àß ¾Ë·ÁÁ® ¿Ô°í,CD8 T cell¿¡primingÀ» ½ÃÅ°´ÂCD103+ȤÀºCD8a+cDC¿¡¼­ ..